3 unknown, 1 completed, 1 enrolling by invitation, 1 recruiting. 8 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Unknown 3, Completed 1, Enrolling by invitation 1, Recruiting 1, Terminated 1, Withdrawn 1 |
Follow Peripheral T-cell Lymphoma: new trials by email Literature Review of Peripheral T-cell Lymphoma trials Research Report on Peripheral T-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) Golidocitinib, Chidamide, Gemcitabine - Peripheral T-cell Lymphoma | Phase 3 | Recruiting | Dizal Pharmaceuticals | 218 | 2024-05-13 | 2026-06-08 |
| Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study BEAC, Cladribine combined with BEAC - Peripheral T-cell Lymphoma | Phase 3 | Unknown | Ruijin Hospital | 266 | 2020-10-17 | 2021-05-11 |
| Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma Cyclophosphamide, pegylated liposomal doxorubicin, Vincristine - Peripheral T-cell Lymphoma | Phase 3 | Unknown | Peking University | 244 | 2019-05-10 | 2019-05-16 |
| Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma Decitabine, Cyclophosphamide, Doxorubicin - Peripheral T-cell Lymphoma | Phase 3 | Unknown | Southwest Hospital, China | 100 | 2018-06-01 | 2018-06-12 |
| BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas Doxorubicin, Vincristine, Etoposide - Peripheral T-cell Lymphoma | Phase 3 | Enrolling by invitation | N.N. Petrov National Medical Research Center of Oncology | 114 | 2013-10-01 | 2025-12-02 |
| Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma Romidepsin + CHOP, CHOP - Peripheral T-cell Lymphoma | Phase 3 | Completed | The Lymphoma Academic Research Organisation | 421 | 2013-01-01 | 2023-01-10 |
| Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients Pralatrexate Injection - Peripheral T-cell Lymphoma | Phase 3 | Terminated | Spectrum Pharmaceuticals, Inc | 21 | 2011-08-01 | 2021-11-19 |
| A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma E7777 - Peripheral T-Cell Lymphoma | Phase 3 | Withdrawn | Eisai Inc. | 2011-03-01 | 2013-11-18 |
Lymphoma, T-Cell, Peripheral (8) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell (1) · Lymphoproliferative Disorders (1)
Hemic and Lymphatic Diseases (8) · Immune System Diseases (8) · Immunoproliferative Disorders (8) · Lymphatic Diseases (8) · Neoplasms (8) · Neoplasms by Histologic Type (8) · Lymphoma (7) · Lymphoma, Non-Hodgkin (7) · Lymphoma, T-Cell (7) · Lymphoproliferative Disorders (7)
Cyclophosphamide (3) · Doxorubicin (3) · Prednisone (3) · Vincristine (3) · 1-dodecylpyridoxal (1) · 10-propargyl-10-deazaaminopterin (1) · BAEC protocol (1) · Brentuximab Vedotin (1) · Decitabine (1) · E7777 fusion protein (1) · Etoposide (1) · Gemcitabine (1) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (1) · liposomal doxorubicin (1) · romidepsin (1)
Dizal Pharmaceuticals (1) · Eisai Inc. (1) · N.N. Petrov National Medical Research Center of Oncology (1) · Peking University (1) · Ruijin Hospital (1) · Southwest Hospital, China (1) · Spectrum Pharmaceuticals, Inc (1) · The Lymphoma Academic Research Organisation (1)
China (3) · Belgium (2) · France (2) · Italy (2) · Spain (2) · United States (2) · Australia (1) · Canada (1) · Germany (1) · Ireland (1) · Israel (1) · New Zealand (1) · Poland (1) · Portugal (1) · Puerto Rico (1)
Chean Eng Ooi (1) · Jieping Chen, MD,PhD (1) · Jun Zhu, PHD (1) · Weili Zhao (1) · Xi Li, MD (1)